Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

First Patient Dosed in DUR-928 Study in COVID-19 Patients with Acute Liver, Kidney Injury

americanpharmaceuticalreviewSeptember 30, 2020

Tag: DUR-928 , COVID-19 , Kidney Injury

PharmaSources Customer Service